Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authorwosidSAYIN, N. CENK/A-5801-2018
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorAybatli, Aysun
dc.contributor.authorKaplan, Petek Balkanli
dc.contributor.authorCicin, Irfan
dc.contributor.authorSut, Necdet
dc.contributor.authorSayin, Cenk
dc.contributor.authorVarol, Fusun
dc.date.accessioned2024-06-12T10:55:27Z
dc.date.available2024-06-12T10:55:27Z
dc.date.issued2013
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe goal of this study was to evaluate the efficacy of CA-125 area under the curve (CA-125 AUC) as a prognostic factor following surgical treatment for ovarian cancer patients. A retrospective analysis was conducted on ninety-five patients with ovarian cancer who had primary treatment in a tertiary center between 2000 and 2010. After either optimal or cytoreductive surgery, all patients underwent adjuvant chemotherapy. CA-125 AUC was calculated for each patient that had a minimum of three CA-125 serum measurements during the treatment period. The mean age at diagnosis and mean survival were 53.9 years (range, 16-75 years) and 35.6 +/- 22.9 months (range, 3.1-95.4 months), respectively. The mean (and median) CA-125 AUC of patients of FIGO stages I, II, III, and IV was 53.0 (42.5), 58.06 (58.06), 97.8 (54.6), and 405.2 (149.3) IU/ml day, respectively (p = 0.004). The mean CA-125 AUC was 57.7, 410.1, and 636.3 IU/ml day for patients with a complete response, partial response, and no response/progressive disease to first-line chemotherapy, respectively (p < 0.001). The CA-125 AUC cut-off level for an overall survival of >= 5 years was 99.75 IU/ml day with a sensitivity of 90.9 % (95 % CI, 70.8-98.6) with 1.27 as positive likelihood ratio. Patients who suffer from ovarian cancer, with a lower CA125 AUC, have a better overall survival than those with a higher CA125 AUC. CA-125 AUC could be used as an independent factor for evaluating the treatment efficacy and chemotherapy response.en_US
dc.identifier.doi10.1007/s12032-012-0447-x
dc.identifier.issn1357-0560
dc.identifier.issue1en_US
dc.identifier.pmid23322523en_US
dc.identifier.scopus2-s2.0-84872107553en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-012-0447-x
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19426
dc.identifier.volume30en_US
dc.identifier.wosWOS:000316800800125en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCA-125 AUCen_US
dc.subjectOvarian Canceren_US
dc.subjectPrognostic Factorsen_US
dc.subjectSerum Half-Lifeen_US
dc.subjectInduction Chemotherapyen_US
dc.subjectCa 125en_US
dc.subjectCa125en_US
dc.subjectSurvivalen_US
dc.subjectRegressionen_US
dc.subjectCarcinomaen_US
dc.subjectKineticsen_US
dc.titleAssessment of CA-125 area under the curve as a prognostic factor in patients with ovarian canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu